Literature DB >> 7297022

Morphine kinetics in cancer patients.

J Säwe, B Dahlström, L Paalzow, A Rane.   

Abstract

Oral and intravenous morphine kinetics were studied in seven patients with cancer who needed continuous treatment with morphine because of severe chronic pain. Single oral (20 to 30 mg) and intravenous (4 mg) doses were given on separate days, followed by repetitive blood sampling for morphine analysis by gas chromatography. Volume of distribution ranged from 0.95 to 3.75 l/kg and serum clearance from 5.0 to 16.1 ml/min/kg. Oral morphine in doses that were more than five times the intravenous dose gave concentrations (at 10 and 120 min after dose) between 38 and 112 ng/ml. During the 0.25- to 8-hr period after the oral dose serum concentrations were higher than after the intravenous dose. There was a variation in oral bioavailability of 15% to 64% and an interindividual variation in terminal half-life from 58 to 465 min. These data warrant careful adjustment of the oral dose under close supervision of the patient at the onset of therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297022     DOI: 10.1038/clpt.1981.214

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  35 in total

1.  Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

Authors:  T J Wilkinson; B A Robinson; E J Begg; S B Duffull; P J Ravenscroft; J J Schneider
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  The role of tramadol in cancer pain treatment--a review.

Authors:  Wojciech Leppert; Jacek Łuczak
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

3.  Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.

Authors:  J Hasselström; N Alexander; C Bringel; J O Svensson; J Säwe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Enterohepatic circulation of opioid drugs. Is it clinically relevant in the treatment of cancer patients?

Authors:  G W Hanks; P J Wand
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

5.  The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.

Authors:  J Hasselström; S Eriksson; A Persson; A Rane; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

6.  The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers.

Authors:  P J Hoskin; G W Hanks; G W Aherne; D Chapman; P Littleton; J Filshie
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

7.  Profound reduction in morphine clearance and liver blood flow in shock.

Authors:  M S Macnab; D J Macrae; E Guy; I S Grant; J Feely
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

8.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

9.  The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.

Authors:  R Pöyhiä; T Seppälä; K T Olkkola; E Kalso
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

10.  Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.

Authors:  G M Peterson; C T Randall; J Paterson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.